Comparative study between Ribavirin and Ribavirin plus intravenous Immunoglobulin against Crimean Congo hemorrhagic fever

Journal of Research in Medical Sciences

Volumn 18, Issue 6, 2013, Pages 497-500

  Salehi, Hassan ^a   Salehi, Marzieh ^a   Adibi, Neda ^a   Salehi, Maryam ^a  

^a ISFAHAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Congo fever; Hemorrhagic; Intravenous Immunoglobulin; Ribavirin; Viral

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; CREATINE KINASE; CREATININE; ELECTROLYTE; IMMUNOGLOBULIN; RIBAVIRIN;

ADJUVANT THERAPY; ADULT; ANEMIA; ARTICLE; BLEEDING; CLINICAL ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; CRIMEAN CONGO HEMORRHAGIC FEVER; DRUG EFFICACY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HOSPITALIZATION; HUMAN; LEUKOCYTE COUNT; LEUKOCYTOSIS; LEUKOPENIA; LIVER FUNCTION TEST; LOADING DRUG DOSE; MALE; MORTALITY; PARTIAL THROMBOPLASTIN TIME; PROTEINURIA; PROTHROMBIN TIME; RANDOMIZED CONTROLLED TRIAL; SINGLE BLIND PROCEDURE; THROMBOCYTE; THROMBOCYTOPENIA; UREA NITROGEN BLOOD LEVEL;

EID: 84881121389     PISSN: 17351995     EISSN: 17357136     Source Type: Journal    
DOI: None     Document Type: Article

References (35)

1. Fisher-Hoch SP, McCormick JB, Swanepoel R, Van Middlekoop A, Harvey S, Kustner HG. Risk of human infection with Crimean-Congo hemorrhage fever virus in a South African rural community. Am J Trop Med Hyg 1992;47:337-45.
2. Gear JH, Thomson PD, Hopp M, Andronikou S, Cohn RJ, Ledger J, et al. Crimean-congo haemorrhagic fever in South Africa. Report of a fatal case in the Transvaal. S Afr Med J 1982;62:576-80.
3. Simpson DI, Knight EM, Courtois G, Williams MC, Weinbren MP, Kibukamusoke JW: Congo virus: a hitherto undescribed virus occurring in Africa. I. Human isolations-clinical notes. East Afr Med J 1967;44:86-92.
4. Papa A, Ma B, Kouidou S, Antoniadis A. Genetic characterization of the mRNA segment of Crimean-Congo hemorrhagea fever virus strains, china. Emerg Infect Dis 2002;8:50-3.
5. Burt FJ, Spencer DC, Leman PA, Patterson B, Swanepoel R. Investigation of tick-borne viruses as pathogens of human in South Africa and evidence of Dugbe virus infection in a patient with prolonged thrombocytopenia. Epidemiol Infect 1996;116:353-61.
6. Chinikar S. The specific serological investigation of suspected human and animals to have Crimean-congo hemorrhagic fever in various parts of Iran using ELISA. Hakim 2002;4:294-300.
7. nd ed. Philadelphia: Elsevier Churchill Livingstone; 2006. p. 762-80.
8. Bird BH, Githinji JW, Macharia JM. Multiple viruses lineages sharing recurrent common ancestry were associated with a large hemorrhagic fever in Kenya. 2006-2007. J Virol 2008;82:11152-66.
9. Deyede VM, Khristova ML, Rollin PE. Crimean congo hemorrhagic fever. J Virol 2006;80:8834-42.
10. World health organization. Fact sheet No, 208. Available from: http://www.who.int/inf-fs/en/fact208Htm/. [Last accessed on 2001].
11. Joubert JR, King JB, Rossouw DJ, Cooper R. A nosocomial outbreak of Crimean-Congo hemorrhagic fever at Tygerberg hospital. Part III. Clinical pathology and pathogenesis. S Afr Med J 1985;68:722-8.
12. Whitehouse CA. Crimean Congo hemorrhagic fever. Antivir Res 2004;64:145-60.
13. Ergonul O. Treatment of Crimean Congo hemorrhagic fever. Antiviral Res 2008;78:125-31.
14. CDC update: Management of patient with suspected viral hemorrhagic fever USA. MMWR 1995;44:475.
15. Peters CJ. Management of patients with high-hazard viruses. Arch virol 2002;8:141.
16. World health organization. Crimean Congo hemorrhagic fever. Geneva: World Health Organization; 2001. Available from: http://www.who.int/mediacentre/factsheets/fs 208/en/[Last accessed 2008 Jul 20].
17. Who Ribavirin. Geneva: WHO; 2008. Available from: http://www.who.int/emlib/medicinedisplay.aspx [Last accessed on 2008 Jul 20].
18. Peters CJ, Rcynold JA. Prophylaxis of rift valley fever and CCHF with antiviral Drugs, immuno cerum, and interferon inducer and a macrophage activator antiviral. Rev Infect Dis 1986;6:285.
19. Bray M. Highly pathogenic RNA viral infection. Challenges for antiviral research. Antiviral Res 2008;78:1-8.
20. Dielt CA, Wernly JA, Pett SB. Extra corporal membrane oxygenation support improves survival of patients with severe Hantavirus cardiopulmonary syndrome. J Thorac Cardiovasc Surg 2008;135:579-84.
21. Robert B. Tcsh: Crimcan congo hemorrhagic fever. Feigin and Cherry's Textbook of Pediatric Infectious Diseases: Expert Consult-Online and Print, 2-Volume. Ralph D, Feigin MD, James Cherry MD, Gail J, Demmler-Harrison MD, Sheldon L, et al. Vol 1, chapter 191. London: Saunders; 2009. p. 2160-1.
22. Fisher Hoch SP, Khan JA. Crimean congo hemorrhagic fever treated with oral Ribaverin. Lancet 1995;346:427-5.
23. Burt FJ, Swanepoel R, Shieh WJ, Smith JF, Leman PA, Greer PW. et al. Immunohistochemical and in situ localization of Crimean-Congo hemorrhagic fever (CCHF) virus in human tissues and implications for CCHF pathogenesis. Arch Pathol Lab Med. 1997 Aug;121:839-46.
24. Shepred AJ, Swanpoel R. Antibody response in Crimean-Congo hemorrhagic fever. Rev infect Dis 1989;11(Suppl 4):S801-6.
25. Salehi H, Mostafavizadeh K, Karimi I, Rostami M, Emami A, Javadi AA, et al. Primitive reports of crimean Congo hemorrhagic fever in Isfahan, Iran. Res Med 1381;1:78-9.
26. Mardani M, Jahromi MK, Naeni KH, Zeinali M. The efficacy of oral ribavirin in the treatment of Crimean-Congo hemorrhagic fever. Clin Infect Dis 2003;36:1613-8.
27. Fisgin NT, Ergonul O, Doganci L, Tulek N. The role of ribavirin in the therapy of Crimean-Congo hemorrhagic fever: Early use is promising. Eur J Clin Microbiol Infect Dis 2009;28:929-33.
28. Izadi S, Salehi M. Evaluation of the efficacy of ribavirin therapy on survival of Crimean-Congo hemorrhagic fever patients: A case-control study. Jpn J Infect Dis 2009;62:11-5.
29. Jahrling PB, Geisber J. Passive immunization of Ebola virus-infected monkeys, with immunoglobulin from immune horse. Arch Virol Suppl 1996;11:135-40.
30. th ICAAC abstracts, V-1908 pp., Chicago, IL, USA, September 2007
31. Jahrling P B, Geisbert TW, Geisbert JB, Swearengen JR, Bray M, Jaax NK, et al. Evaluation of immune globulin and recombinant interferon-α2b for treatment of experimental Ebola virus infections. J Infect Dis 1999; 179(Suppl. 1):S224-S234.
32. Mupapa K, Massambe M, Kibadi K, Kuvula K, Bwaka A, Kipasa M, et al. Treatment of Ebola hemorrhagic fever with blood transfusion from convalescent patients. J Infect Dis 1999;179(Suppl 1):S18-23.
33. Sadek RF, Khan AS. Ebola hemorrhagic fever determination of survival. J Infect Dis 1999;79:24-77.
34. Gupta M, Mahanty S, Bray M, Ahmed R, Rollin PE. Passive transfer of antibodies protects immunocompetent and imunodeficient mice against lethal Ebola virus infection without complete inhibition of viral replication. J Virol. 2001 May;75:4649-54.
35. Sullivan KM, Kopecky KJ, Jocom J, Fisher L, Buckner CD, Meyers JD, et al. Immunimodulatory and antimicrobial efficacy of Intravenous Immunoglubulin in bore narrow transplantation. N Engl J Med 1990;323:705-12.